A pressure-sensitive adhesive matrix and a patch are disclosed. The pressure-sensitive adhesive matrix includes the following components: in parts by mass, 60-85 parts of an acrylate pressure-sensitive adhesive, 1-20 parts of a polyol, and 5-30 parts of a plasticizer. The pressure-sensitive adhesive matrix has a micro-phase separation structure, and fine polyol droplets are uniformly dispersed in a homogeneous phase structure compounded by the acrylate pressure-sensitive adhesive and plasticizer. The pressure-sensitive adhesive matrix exhibits water absorbability and moisture retention ability, so that the adhesion between the matrix and skin is not adversely influenced by TEWL. The adhesion of the matrix is gradually improved after absorbing water, therefore the adhesion time is increased.

A pressure-sensitive adhesive matrix and a patch are disclosed. The pressure-sensitive adhesive matrix includes the following components: in parts by mass, 60-85 parts of an acrylate pressure-sensitive adhesive, 1-20 parts of a polyol, and 5-30 parts of a plasticizer. The pressure-sensitive adhesive matrix has a micro-phase separation structure, and fine polyol droplets are uniformly dispersed in a homogeneous phase structure compounded by the acrylate pressure-sensitive adhesive and plasticizer. The pressure-sensitive adhesive matrix exhibits water absorbability and moisture retention ability, so that the adhesion between the matrix and skin is not adversely influenced by TEWL. The adhesion of the matrix is gradually improved after absorbing water, therefore the adhesion time is increased.

Particles with a spatial and/or temporal release profile for delivery of different agents at different times to the same cells of a subject have been developed. The particles include a core polymeric particle containing a polymer and a first agent, a tethering moiety, covalent linker or covalent linkage attached to the core particle, and a tethered particle attached to the particle via the tethering moiety, covalent linker or covalent linkage and containing a second agent, where the agents are released at different times within or to the same cells. The first and second agents may be a therapeutic or prophylactic agent, such as an antigen, an immunomodulator, an anti-neoplastic agent, a hormone, an inhibitor, etc. The particles may form compositions for treating diseases with a spatial and/or temporal treatment regimen.

Combination therapy methods, compositions and kits Invention relates to combinations comprising: a) a compound of formula (I)

##STR00001##

or a pharmaceutically or veterinary acceptable salt thereof, wherein:
R.sub.1 R.sub.2 and R.sub.3 have particular meaning; and (b) one or more drugs selected from the group consisting of i) a compound of formula (IV), or a pharmaceutically or veterinary acceptable salt thereof,

##STR00002##

wherein R.sub.5 and R.sub.6 have particular meaning, ii) a sphingosine-1-phosphate receptor inhibitor (S1PR modulator), and iii) a Signal transducer and activator of transcription 3 (STAT3) inhibitor. Particular combinations and single pharmaceutical compositions and kits of parts are disclosed. These combinations, single pharmaceutical compositions and kits of parts are for use in the treatment and/or prevention of an inflammatory neurological disease or condition which can result in the destruction or degeneration of axons or myelin in a subject in need thereof

Combination therapy methods, compositions and kits Invention relates to combinations comprising: a) a compound of formula (I)

##STR00001##

or a pharmaceutically or veterinary acceptable salt thereof, wherein:
R.sub.1 R.sub.2 and R.sub.3 have particular meaning; and (b) one or more drugs selected from the group consisting of i) a compound of formula (IV), or a pharmaceutically or veterinary acceptable salt thereof,

##STR00002##

wherein R.sub.5 and R.sub.6 have particular meaning, ii) a sphingosine-1-phosphate receptor inhibitor (S1PR modulator), and iii) a Signal transducer and activator of transcription 3 (STAT3) inhibitor. Particular combinations and single pharmaceutical compositions and kits of parts are disclosed. These combinations, single pharmaceutical compositions and kits of parts are for use in the treatment and/or prevention of an inflammatory neurological disease or condition which can result in the destruction or degeneration of axons or myelin in a subject in need thereof

Methods and compositions for treating or preventing C. difficile infections, particularly recurring C. difficile infections are described. The compositions for use in treating C. difficile include at least one agent that enhances a biological activity of interleukin-13 (IL-13), such as a recombinant IL-13 peptide or an agent that neutralizes the interleukin-13 (IL-13) decoy receptor, interleukin-13 receptor subunit alpha-2 (IL-13Ra2). Additionally or alternatively, the compositions can include a interleukin-4 (IL-4) peptide. The methods can result in more rapid recovery from CDI and decreased weight loss, e.g., than treatment without the neutralizing agent.

Methods and compositions for treating or preventing C. difficile infections, particularly recurring C. difficile infections are described. The compositions for use in treating C. difficile include at least one agent that enhances a biological activity of interleukin-13 (IL-13), such as a recombinant IL-13 peptide or an agent that neutralizes the interleukin-13 (IL-13) decoy receptor, interleukin-13 receptor subunit alpha-2 (IL-13Ra2). Additionally or alternatively, the compositions can include a interleukin-4 (IL-4) peptide. The methods can result in more rapid recovery from CDI and decreased weight loss, e.g., than treatment without the neutralizing agent.

The present invention can inhibit dihydrofolate reductase in a microorganism. In some aspects, it may also suppress pigment formation in gram negative bacteria. The suppression of pigment formation can also mediate virulence suppression on other Gram negative bacteria. As such, the compounds may be used for microbial infections. The compounds can potentiate the effects of one or more antimicrobial agents when co-administered. Compositions including the compounds are provided. The composition can further include at least one antibiotic.

The present invention can inhibit dihydrofolate reductase in a microorganism. In some aspects, it may also suppress pigment formation in gram negative bacteria. The suppression of pigment formation can also mediate virulence suppression on other Gram negative bacteria. As such, the compounds may be used for microbial infections. The compounds can potentiate the effects of one or more antimicrobial agents when co-administered. Compositions including the compounds are provided. The composition can further include at least one antibiotic.

Provided herein are protein translation inhibitors and pharmaceutical compositions thereof that bind to an RNA Recognition motif in heterogeneous ribonucleoprotein A18 to inhibit binding to mRNA transcripts thereby inhibiting protein synthesis. Also provided is a method for treating a cancer by administering a pharmaceutically acceptable amounts of at least one of the protein translation inhibitors.